EICHORCondition: Clinical Stage IV Cutaneous Melanoma AJCC v8 · Locally Advanced Melanoma · Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 · Sponsor: ECOG-ACRIN Cancer Research Group
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF V600E/K melanoma. Hydroxychloroquine may cause cell death in tumor cells that rely on a process called "autophagy" for survival. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine together with dabrafenib and trametinib may work better than dabrafenib and trametinib alone to shrink and stabilize the cancer.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | — |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | — |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | — |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | — |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | — |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | — |
| Katmai Oncology Group | Anchorage, Alaska, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| Cancer Center at Saint Joseph's | Phoenix, Arizona, United States | — |
| Mayo Clinic Hospital in Arizona | Phoenix, Arizona, United States | — |
| Mayo Clinic in Arizona | Scottsdale, Arizona, United States | — |
| Mercy Hospital Fort Smith | Fort Smith, Arkansas, United States | — |
+ 187 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04527549